Recorded Presentation from the NCCN 2018 Nursing Program Webinar Series - Management of Hypersensitivity Reactions to Systemic Therapy
Infusion-related HSR to systemic therapy is a serious adverse effect that significantly impacts disease management, quality of life, and life expectancy. Careful assessment of patients prior to initiating systemic therapy would enable the identification of patients at higher risk for HSR. A thorough understanding of the pathophysiology of different types of infusion-related HSR is critical for the early recognition of signs and symptoms as well as implementation of effective prophylactic measures to minimize the risk of HSR. Nurse practitioners require ongoing education that would provide expert guidance necessary for the optimal management of infusion-related HSR without compromising the curative potential of anticancer therapy.
This educational program is designed to meet the educational needs of oncology nurses who manage patients with cancer.
Following this activity, participants should be able to:
- Discuss the pathophysiology of the different types of infusion-related HSR to chemotherapeutic agents and MABs.
- Review the strategies used for the prevention and treatment of infusion-related HSR to systemic therapy.
- Develop an evidence-based treatment plan for the management of infusion-related HSR in patients receiving systemic therapy.
Barbara Rogers, CRNP, MN, AOCN, ANP-BC
Fox Chase Cancer Center
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses the following relevant financial relationships:
Barbara Rogers, CRNP, MN, AOCN, ANP- BC
Bristol-Myers Squibb Company: Product/Speakers Bureau
Gilead Pharmaceuticals: Consulting Fees, Honoraria
Merck & Co., Inc.: Consulting Fees, Honoraria
Seattle Genetics: Product/Speakers Bureau
Takeda Pharmaceuticals North America, Inc.: Consulting Fees, Honoraria
Teva Pharamceuticals: Product/Speakers Bureau
NCCN Staff Disclosures
The NCCN Activity Planning staff listed below discloses no relevant financial relationships:
Kimberly Bayer; Melissa Esplen; Mark A. Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Karen Kanefield; Heather Matt; Joan S. McClure, MS; Diane McPherson; Melanie Moletzsky; Lisa Perfidio, MS; Liz Rieder; Shannon Ryan; Kathy Ann Smith, CMP, CHCP; Melinda Somasekhar, PhD (Employed by NCCN until 10/30/17)
The NCCN Activity Planning staff listed below discloses the following relevant financial relationships:
Donald Harting, ELS, CHCP
Laboratory Corporation of America (LabCorp): Equity interest/Stock Options
Boston Scientific Corporation: Equity Interest/Stock Options
Pfizer Inc.: Equity Interest/Stock Options
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Hema Sundar, PhD
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
NCCN designates this educational activity for a maximum of 0.91 contact hour.
- 0.91 ANCC contact hours
- 0.91 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing